Search Results - "HAHNE, J.C"

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro by HAHNE, J.C, HONIG, A, MEYER, S.R, GAMBARYAN, S, WALTER, U, WISCHHUSEN, J, HÄUSSLER, S.F.M, SEGERER, S.E, FUJITA, N, DIETL, J, ENGEL, J.B

“…Platinum resistance is the most crucial problem for treatment of ovarian cancer. Increasing evidence points towards AKT overexpression as a mechanistic reason…”
Get full text

2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial by Sclafani, F, Chau, I, Cunningham, D, Peckitt, C, Lampis, A, Hahne, J.C, Braconi, C, Tabernero, J, Glimelius, B, Cervantes, A, Begum, R, Castro, D. Gonzalez De, Hulkki Wilson, S, Eltahir, Z, Wotherspoon, A, Tait, D, Brown, G, Oates, J, Valeri, N

Get full text

2326P Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy by Ghidini, M., Hahne, J.C., Senti, C., Tomasello, G., Ratti, M., Heide, T., Garrone, O., Cortellini, A., Passalacqua, R., Valeri, N.

Get full text

Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease by Ghidini, M., Hahne, J.C., Senti, C., Lampis, A., Ratti, M., Pizzo, C., Tomasello, G., Passalacqua, R., Valeri, N.

Get full text

1889P - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease by Ghidini, M., Hahne, J.C., Senti, C., Lampis, A., Ratti, M., Pizzo, C., Tomasello, G., Passalacqua, R., Valeri, N.

“…Liquid biopsies (LB) allow monitoring of genetically different and co-occurring cancer cell clones. In metastatic colorectal cancer (mCRC), circulating-free…”
Get full text

Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients by Hahne, J.C., Lampis, A., Ghidini, M., Ratti, M., Salati, M., Senti, C., Passalacqua, R., Cascione, L., Braconi, C., Sansom, O.J., Fassan, M., Valeri, N.

Get full text

1953P - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients by Hahne, J.C., Lampis, A., Ghidini, M., Ratti, M., Salati, M., Senti, C., Passalacqua, R., Cascione, L., Braconi, C., Sansom, O.J., Fassan, M., Valeri, N.

“…Monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) such as cetuximab or panitumumab are used for the treatment of metastatic colorectal…”
Get full text

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial by Smyth, E.C., Nyamundanda, G., Cunningham, D., Fontana, E., Ragulan, C., Tan, I.B., Lin, S.J., Wotherspoon, A., Nankivell, M., Fassan, M., Lampis, A., Hahne, J.C., Davies, A.R., Lagergren, J., Gossage, J.A., Maisey, N., Green, M., Zylstra, J.L., Allum, W.H., Langley, R.E., Tan, P., Valeri, N., Sadanandam, A.

“…Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph…”
Get full text

Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage by Lampis, A., Carotenuto, P., Hedayat, S., Previdi, M.C., Zito, D., Sclafani, F., Parisi, C., Hahne, J.C., Hallsworth, A., Kirkin, V., Young, K., Kouvelakis, K., Azevedo, S.X., Vasiliki, M., Scarpa, A., Cunningham, D., Chau, I., Valeri, N., Fassan, M., Braconi, C.

Get full text

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer by Lote, H., Spiteri, I., Ermini, L., Vatsiou, A., Roy, A., McDonald, A., Maka, N., Balsitis, M., Bose, N., Simbolo, M., Mafficini, A., Lampis, A., Hahne, J.C., Trevisani, F., Eltahir, Z., Mentrasti, G., Findlay, C., Kalkman, E.A.J., Punta, M., Werner, B., Lise, S., Aktipis, A., Maley, C., Greaves, M., Braconi, C., White, J., Fassan, M., Scarpa, A., Sottoriva, A., Valeri, N.

“…Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers…”
Get full text

Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: Looking for prognostic biomarkers by Ratti, M., Valeri, N., Hahne, J.C., Lampis, A., Ghidini, M., Tomasello, G., Tanzi, G., Toppo, L., Pizzo, C., Donida, B., Senti, C., Salati, M., Trombatore, M., Fassan, M., Passalacqua, R.

Get full text

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial by Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J.C., Braconi, C., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., Gonzalez De Castro, D., Hulkki Wilson, S., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Valeri, N.

“…Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T >…”
Get full text

Prognostic value of the immune-related transcriptome in biliary tract cancers by Ghidini, M., Cascione, L., Lampis, A., Pandolfo, R., Carotenuto, P., Trevisani, F., Hahne, J.C., Zito, D., Guzzardo, V., Zerbi, A., Torzilli, G., Roncalli, M., Rimassa, L., Santoro, A., Fassan, M., Valeri, N., Braconi, C.

Get full text

EGFR amplification (amp) and survival in the REAL-3 trial by Smyth, E., Kouvelakis, K., Cunningham, D., Hahne, J.C., Peckitt, C., Vlachogiannis, G., Watkins, D., Rao, S., Starling, N., Wilson, S.H., Waddell, T.S., Okines, A., Crosby, T., Mansoor, W., Wadsley, J., Middleton, G., Wotherspoon, A., Chau, I., Valeri, N.

Get full text

Retrospective analysis of the role of adjuvant chemotherapy and microRNAs expression in resected cholangiocarcinomas (CCAs) by Ghidini, M., Trevisani, F., Fassan, M., Cascione, L., Hahne, J.C., Lampis, A., Cheong, I.H., Scarpa, A., Vicentini, C., Zerbi, A., Torzilli, G., Roncalli, M., Rimassa, L., Valeri, N., Santoro, A., Braconi, C.

Get full text

KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial by Sclafani, F., Chau, I., Cunningham, D., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., De Castro, D. Gonzalez, Wotherspoon, A., Capdevila, J., Glimelius, B., Cervantes, A., Begum, R., Lote, H., Mentrasti, G., Hahne, J.C., Tait, D., Brown, G., Valeri, N.

Get full text

Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas by Angerilli, V., Fontana, E., Lonardi, S., Sbaraglia, M., Borelli, B., Munari, G., Salmaso, R., Guzzardo, V., Spolverato, G., Pucciarelli, S., Pilati, P., Hahne, J.C., Bergamo, F., Zagonel, V., Dei Tos, A.P., Sadanandam, A., Loupakis, F., Valeri, N., Fassan, M.

“…Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology,…”
Get full text

Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production by Herchenröder, O, Hahne, J.C, Meyer, W.K.-H, Thiesen, H.-J, Schneider, J

“…The Krüppel-associated box (KRAB) domain has been described as a eukaryotic repressor of transcription. We show that fusion of KRAB to DNA-binding-domains…”
Get full text

Studies on the role of osteopontin-1 in endometrial cancer cell lines by Hahne, J.C., Meyer, S.R., Kranke, P., Dietl, J., Guckenberger, M., Polat, B., Hönig, A.

“…Background Osteopontin-1 is a well characterized protein in many tumour entities. Multiple roles in the processes invasion, metastasis and angiogenesis of…”
Get full text

PO-346 Defining microRNA mediated regulation of metabolic pathways involved in colon cancer progression (BST1-microRNA interactions) by Damavandi, M Darvish, Vlachogiannis, G, Nyamundanda, G, Lampis, A, Hedayat, S, Parkes, H, Hahne, JC, Sadanandam, A, Sansom, O, Valeri, N

“…IntroductionColorectal cancer (CRC) is the third most common cause of cancer related death in the world. Progressive accumulation of mutations in oncogenic and…”
Get full text